Get regular updates to your inbox.
I’ll always feel when the seasons are changing by the way my skin reacts. Here in Vienna, autumn is slowly coming to an end and winter is coming, slowly crawling into our smallest crevices. I not only recognize winter when it gets darker outside and the temperature drops, but I…
Read more
The U.S. Food and Drug Administration (FDA) has granted priority review to an application seeking approval of pz-cel (prademagene zamikeracel) — a cell therapy previously known as EB-101 — for people with recessive dystrophic epidermolysis bullosa (RDEB). Granting priority review shortens the time it will take the agency to…
EB Research Partnership (EBRP), an organization dedicated to funding research into treatments for epidermolysis bullosa (EB), has raised more than $5 million through a three-day series of events in October. The outcome is “beyond what we could have ever imagined,” Michael Hund, CEO of EBRP, said in a…
Inflammation occurring early in the course of recessive dystrophic epidermolysis bullosa (RDEB) may create conditions for the disease to progress and for cancer to grow in the skin, a mouse study suggests. Although further studies are necessary, the findings “underscore the essential role of inflammation in RDEB pathophysiology [disease]…
Becoming educated and informed about epidermolysis bullosa is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your EB journey.
There is no cure for EB yet, but there are treatments that can help manage the disease. Learn more about the approved and experimental therapies here.
Get regular updates to your inbox.
